76 results about "Liquid oral" patented technology

The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.

Oral liquid colchicine formulations are described herein. Methods of using the oral liquid colchicine formulations are also provided.

The disclosure provides liquid compositions configured for oral use, the liquid composition comprising water in an amount of about 40% by weight or higher, based on total weight of the composition, a flavoring agent or an active ingredient or both a flavoring agent and an active ingredient, and one or more additional components selected from the group consisting of sweeteners, humectants, and alkali metal salts, wherein the composition has a water activity (Aw) of about 0.85 or lower. The liquid compositions are generally suitable for spraying into the oral cavity.

The present invention provides liquid oral dosage form of lipid lowering agent suitable for oral administration to human or animals.

The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.

The present invention provides liquid oral dosage form of lipid lowering agent suitable for oral administration to human or animals.

The object of the present invention is to provide a non-invasive agent that, in particular, exhibits a skin-improving effect and reduces the visible signs of aging. For this purpose, the invention provides a liquid oral composition as a food supplement or dietary food, comprising liquid marine hydrolyzed collagen peptides obtained from cod skin.

The present invention pertains to stable pharmaceutical compositions comprising cabozantinib or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient, which does not contain glidant(s). Preferably, the pharmaceutically acceptable salts of cabozantinib is cabozantinib S-malate. Furthermore, the present invention also covers liquid oral pharmaceutical composition and injectable dosage forms of cabozantinib or pharmaceutically acceptable salts thereof.

The present invention aims to provide a liquid oral composition that can suppress the reduction in flavor expression caused by glycyrrhizic acid or its salts by incorporating acyl amino acids or their salts. [Solution] A liquid oral composition comprising: (A) component: at least one selected from the group consisting of glycyrrhizic acid and its salts; (B) component: at least one selected from the group consisting of acyl amino acids and their salts; and (C) component: a fragrance, wherein the ratio of the content of component (A) to the content of component (B) is 0.625 to less than 2.2 when component (B) contains acyl sarcosine and its salts, and 0.03 to less than 5 when component (B) does not contain acyl sarcosine and its salts, and substantially free of ethyl alcohol.

A liquid oral composition comprising the following component (a): at least one component selected from tranexamic acid and salts thereof, and component (b): a perfume; and satisfies at least one of the following conditions 1 and 2. (Condition 1) The composition further contains the following component (c): a surfactant having an HLB value of 13.0-20.0, wherein the mass ratio (c) / ((a) + (b)) is 3.5 or more. (Condition 2) The color difference [Delta] E * is 0.0-2.5.

The present invention provides liquid oral dosage form of lipid lowering agent suitable for oral administration to human or animals.

The utility model discloses a multifunctional drainage liquid oral taking cup, and relates to the technical field of drinking cups. The multifunctional drainage liquid oral taking cup comprises a cup body and a cup cover, the cup cover covers the top of the cup body, a drainage liquid injection opening and a drainage liquid direct drinking opening are formed in the two sides of the top of the cup cover respectively, the drainage liquid injection opening and the drainage liquid direct drinking opening are separated, unfiltered drainage liquid can be prevented from being directly drunk, and the multifunctional drainage liquid oral taking cup is provided with a double-drinking-opening flip cover design. Daily sealing protection of the drainage liquid injection opening and the drainage liquid direct drinking opening is achieved, particularly, the sealing rubber plug is arranged in the outer cover covering the drainage liquid direct drinking opening, the sealing performance is further improved, the smell of the drainage liquid can be covered, the discomfort of a patient taking the drainage liquid is relieved, and the drainage liquid can be prevented from being poured easily. And besides the use of medical consumables is saved, the convenience of filtering the drainage liquid is also increased, and the backflow prevention design can also prevent a patient from pouring out the drainage liquid from the drainage liquid injection port by mistake for drinking, so that the use is convenient.

The present invention aims to provide a liquid oral composition that does not contain ethyl alcohol and can sufficiently suppress the formation of precipitates during high-temperature storage. [Solution] The present invention provides a liquid oral composition that is substantially free of ethyl alcohol and comprises (A) component: dextranase and (B) component: xanthan gum, preferably further comprising (C) component. It is preferable that the content of component (A) is 0.0077 to 1.54% by mass, the content of component (B) is 0.01 to 1.0% by mass, and the mass ratio of the content of component (A) to the content of component (B) ((A) / (B)) is 0.6 to 150.

The present invention relates to hydrophobic sorbent compositions suitable for human or animal consumption. In particular, the compositions comprise fine coffee grounds, and may further comprise activated charcoal. Formulated in solid or liquid oral dosage forms, the compositions are useful as a dietary supplement.

The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.

This invention provides a liquid oral composition with excellent retention properties for dodecylpyridinium chloride. [Solution] The liquid oral composition contains dodecylpyridinium chloride and a compound having a hydroxyl group.

A liquid formulation of oral administration of netupitant and palonosetron, which is effective, chemically stable and physiologically balanced in safety and efficacy.

The application provides a sugar alcohol solvent and its application in preparation of a product containing ginkgo leaf extract, and belongs to the technical field of food and health care products. The sugar alcohol solvent comprises xylitol, and the mass percentage of xylitol in the sugar alcohol solvent is 30-50%. The sugar alcohol solvent is safe and non-toxic, has simple preparation process and low cost, can be used as a solubilizing solvent for the ginkgo leaf extract, can improve the solubility of the ginkgo leaf extract without affecting the stability and biological activity of ginkgolides and ginkgo flavones in the ginkgo leaf extract, can be used as an intermediate purification solvent for preparation of ginkgolide monomers, is safe and non-toxic, and can be used as a new solvent for the ginkgo leaf extract to prepare a liquid oral ginkgo leaf extract, so that liquid health care is realized, and safe drug delivery is realized for diagnosis and treatment of cardiovascular and cerebrovascular diseases of special groups (such as diabetic patients).

The present invention aims to provide a colorant composition that contains core-shell particles encapsulating a colorant and that can be used for forming a pattern such as a line in a liquid such as a drink, as well as a liquid oral composition containing the colorant composition and a production method therefor, and a method for forming a pattern in a liquid. The present invention relates to a colorant composition containing a first liquid and core-shell particles, the core-shell particles each including a core and a shell that encapsulates the core, the core containing an oily component and a colorant, the shell containing a cationic polymer, the cationic polymer being edible, the core-shell particles being dispersed in the first liquid.

Liquid oral pilocarpine formulations are described herein. Methods of using the liquid oral pilocarpine formulations are also provided.

The utility model provides an extrusion device of a quantity control type water aqua oral medicine suction tube, and relates to the technical field of extrusion equipment. An extrusion device of a quantity control type water aqua oral medicine suction tube comprises an extrusion barrel, a drying box and a driving motor, the drying box is fixedly connected to the top of the extrusion barrel, one end of the drying box is communicated with a feeding port of the extrusion barrel, and a storage barrel is fixedly connected to the top of the end, away from the feeding port of the extrusion barrel, of the drying box; a valve is fixedly connected to the material storage barrel, and an inclined movable plate is arranged in the drying box. Raw materials in the material storage barrel fall onto a movable plate in the drying box by opening a valve on the material storage barrel, the raw materials slide on the inclined movable plate to the inclined end of the movable plate, the raw materials on the movable plate are dried through a hot air mechanism, and the sliding path of the raw materials on the movable plate is prolonged under the action of a material baffle. And the drying effect on the raw materials is improved, and the quality of produced straws is improved.

The present invention aims to provide a colorant composition that contains core-shell particles encapsulating a colorant and that can be used for forming a pattern such as a line in a liquid such as a drink, as well as a liquid oral composition containing the colorant composition and a production method therefor, and a method for forming a pattern in a liquid. The present invention relates to a colorant composition containing a first liquid and core-shell particles, the core-shell particles each including a core and a shell that encapsulates the core, the core containing an oily component and a colorant, the shell containing a cationic polymer, the cationic polymer being edible, the core-shell particles being dispersed in the first liquid.

The present invention relates to stable liquid oral compositions of cyclophosphamide having extended stability, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cyclophosphamide. The invention also relates to a kit comprising stable liquid oral compositions of cyclophosphamide.

The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.

To provide a liquid oral composition that contains glycyrrhizic acid and its derivatives and potassium nitrate, exhibits a desensitizing effect, effectively masks the salty or off-taste of potassium nitrate, and ensures favorable stability of glycyrrhizic acid salts.SOLUTION: There is provided a liquid oral composition comprising: (A) glycyrrhizic acid, or salts of glycyrrhizic acid such as sodium salt, potassium salt, or ammonium salt; (B) an inorganic water-soluble potassium salt such as potassium nitrate or potassium fluoride; and (C) a pyrrolidone carboxylic acid salt such as sodium pyrrolidone carboxylate, calcium pyrrolidone carboxylate, magnesium pyrrolidone carboxylate, zinc pyrrolidone carboxylate, or potassium pyrrolidone carboxylate.SELECTED DRAWING: None

A method of treating and / or preventing symptoms of Rett syndrome (RTT) in a patient such as a patient previously diagnosed with Rett syndrome, by administering an effective dose of a 5-HT1D, 5-HT2A, 5-HT2C or sigma-1 receptor agonist (e.g., fenfluramine or its pharmaceutically acceptable salt) to that patient. RTT patients are treated at a preferred dose of less than about 1.0 mg / kg / day and may be administered as fenfluramine in an amount of between 0.2 to 0.8 mg / kg / day, to a maximum of 30 mg / day in a liquid oral dose.

To provide a citric acid-derived sourness inhibitor that can inhibit sourness from citric acid.SOLUTION: The present invention provides a citric acid-derived sourness inhibitor for use as an additive or an ingredient in a citric acid-containing liquid oral composition. The citric acid-derived sourness inhibitor contains citric acid and potassium citrate. The pH of the citric acid-containing liquid oral composition containing the citric acid-derived sourness inhibitor is 5-8. The total citric acid content in the citric acid-containing liquid oral composition containing the citric acid-derived sourness inhibitor is 0.05-1.0 mass%. The content of potassium derived from the potassium citrate is 0.4-1.0 pt.mass relative to the total citric acid 1 pt.mass. The citric acid-containing liquid oral composition containing the citric acid-derived sourness inhibitor is free of sweeteners or has a sweetness intensity equivalent to a sucrose solution of 5 mass% or less.SELECTED DRAWING: None

A dietary supplement composition in the form of a carbonated beverage comprising a concentrate of red cherry, an extract of Goji berry, magnesium, and tryptophan, and comprising at least 0.5mg of phyt